share_log

Supernus Pharmaceuticals Analyst Ratings

Supernus Pharmaceuticals Analyst Ratings

超級藥品分析師評級
Benzinga Analyst Ratings ·  2023/01/23 07:13
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/23/2023 16.6% Piper Sandler $40 → $47 Maintains Overweight
08/31/2022 -5.73% Piper Sandler $33 → $38 Maintains Overweight
04/13/2021 -0.77% Jefferies $25 → $40 Upgrades Hold → Buy
06/16/2020 -23.1% Piper Sandler $25 → $31 Upgrades Neutral → Overweight
06/15/2020 -40.46% Jefferies → $24 Reinstates → Hold
04/16/2020 -40.46% Stifel $25 → $24 Maintains Hold
11/07/2019 -42.94% Stifel $55 → $23 Downgrades Buy → Hold
11/06/2019 — Jefferies Downgrades Buy → Hold
12/17/2018 56.29% Mizuho $61 → $63 Maintains Buy
11/12/2018 61.25% B. Riley Securities $68 → $65 Maintains Buy
09/18/2018 51.33% Mizuho → $61 Initiates Coverage On → Buy
08/09/2018 43.88% Jefferies $55 → $58 Maintains Buy
05/25/2018 48.85% Stifel $50 → $60 Maintains Buy
02/01/2018 63.73% Berenberg → $66 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年1月23日 16.6% 派珀·桑德勒 $40→$47 維護 超重
2022年08月31日 -5.73% 派珀·桑德勒 $33→$38 維護 超重
04/13/2021 -0.77% 傑富瑞 $25→$40 升級 持有→購買
06/16/2020 -23.1% 派珀·桑德勒 $25→$31 升級 中性→超重
2020/06/15 -40.46% 傑富瑞 →$24 恢復 →保留
04/16/2020 -40.46% Stifel $25→$24 維護 保持
2019/07/11 -42.94% Stifel $55→$23 評級下調 購買→Hold
2019/06/11 - 傑富瑞 評級下調 購買→Hold
2018年12月17日 56.29% 瑞穗 $61→$63 維護 買
2018年11月12日 61.25% B.萊利證券 $68→$65 維護 買
2018年09月18日 51.33% 瑞穗 →$61 開始承保 →購買
2018年08月09日 43.88% 傑富瑞 $55→$58 維護 買
2018年05月25日 48.85% Stifel $50→$60 維護 買
2018年02月01日 63.73% 貝倫伯格 →$66 開始承保 →購買

What is the target price for Supernus Pharmaceuticals (SUPN)?

Supernus PharmPharmticals(SUPN)的目標價是多少？

The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on January 23, 2023. The analyst firm set a price target for $47.00 expecting SUPN to rise to within 12 months (a possible 16.60% upside). 2 analyst firms have reported ratings in the last year.

派珀·桑德勒於2023年1月23日報道了Supernus製藥公司(納斯達克代碼：SUPN)的最新目標價。這家分析公司將目標價定為47.00美元，預計SUPN將在12個月內上漲至16.60%(可能上漲16.60%)。去年有兩家分析公司公佈了評級。

What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?

Supernus PharmPharmticals(SUPN)的最新分析師評級是多少？

The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.

分析師對Supernus PharmPharmticals(納斯達克代碼：SUPN)的最新評級由Piper Sandler提供，Supernus PharmPharmticals維持其增持評級。

When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?

Supernus PharmPharmticals(SUPN)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Supernus製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Supernus製藥的上一次評級是在2023年1月23日提交的，所以你應該預計下一次評級將在2024年1月23日左右的某個時候公佈。

Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?

分析師對Supernus PharmPharmticals(SUPN)的評級正確嗎？

While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $40.00 to $47.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $40.31, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Supernus PharmPharmticals(SUPN)評級維持不變，目標價在40.00美元至47.00美元之間。Supernus PharmPharmticals(SUPN)目前的交易價格為40.31美元，在分析師的預測區間內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論